Recently, the FDA (Food and Drug Administration) approved testing of breast cancer patients with PIK3CA mutations using tumor tissue and/or circulating tumor DNA isolated from plasma specimens [43]. The gene discussed is PIK3CA; the disease is breast carcinoma.